Compare Dow Inc (DOW) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Incyte Corporation — how do they compare? Dow Inc trades at $28.85 (market cap $20.65B), while Incyte Corporation trades at $112.65 (market cap $22.85B). The key difference: Dow Inc and Incyte Corporation are close in size by market cap, and Dow Inc pays a 4.9% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and Incyte Corporation for 33 Days on average.
| DOW | INCY | |
|---|---|---|
Market Cap | $20.65B | $22.85B |
Volume | 14,126,943 | 1,927,029 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $129.93 |
52-Week Low | $20.65 | $83.80 |
Typical Hold Time | 82 Days | 33 Days |
Enterprise Value | $36.34B | $18.35B |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $27.77, down 1.38% with bearish technical signals. The company faces fundamental challenges with negative net income margin (-3.13%) and ROE (-7.86%) despite beating recent EPS estimates. Revenue declined from $56.9B in 2022 to $40.0B in 2025, though 2026 projections show modest recovery to $41.3B. Analyst consensus is mixed with 28% buy ratings but a $34.22 price target suggesting 23% upside potential from current levels.
DOW presents a high-risk opportunity with significant valuation disconnect. While technicals are bearish and profitability metrics weak, the stock trades at attractive valuation multiples (P/S: 0.5x, P/B: 1.3x) with dividend support. Key risks include ongoing margin pressure, declining operating cash flow trend, and rising debt-to-asset ratio approaching 30%. The investment case hinges on earnings recovery and operational turnaround execution.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
